Odra, świnka i różyczka
Rokowania, prognozy i postęp choroby

Szczepionka MMR wykazuje wysoką skuteczność w profilaktyce odry, świnki i różyczki, zapewniając po pełnym schemacie dwóch dawek ochronę na poziomie 97% przed odrą, około 99% przed odrą i różyczką oraz około 88% przed świnką. Ochrona immunologiczna rozwija się w ciągu dwóch tygodni od podania dawki, a u większości osób odporność utrzymuje się przez całe życie, z wyjątkiem świnki, gdzie możliwe jest osłabienie odporności i konieczność dawki przypominającej. Szczepionka znacząco redukuje ryzyko hospitalizacji z powodu chorób zakaźnych (HR = 0,10; 95% CI: 0,03-0,34 dla odry i świnki) oraz infekcji dolnych dróg oddechowych (HR: 0,18; 95% CI: 0,07-0,48), co wskazuje na jej szerokie korzyści zdrowotne wykraczające poza choroby docelowe.

  1. Prognoza po szczepieniu MMR (odra, świnka i różyczka)
    1. Skuteczność ochrony przed chorobami docelowymi
    2. Złagodzenie przebiegu chorób u osób zaszczepionych
    3. Wpływ na zmniejszenie hospitalizacji
    4. Wpływ momentu szczepienia na prognozę
    5. Odporność zbiorowiskowa i wpływ populacyjny
    6. Bezpieczeństwo długoterminowe
  2. Podsumowanie prognozy po szczepieniu MMR
    1. Kolejne rozdziały

Prognoza po szczepieniu MMR (odra, świnka i różyczka)

Szczepionka przeciwko odrze, śwince i różyczce (MMR) stanowi jedno z najbardziej skutecznych narzędzi profilaktycznych w zapobieganiu tym chorobom zakaźnym, oferując długotrwałą ochronę oraz korzystny wpływ na ogólny stan zdrowia populacji dziecięcej. Prognozy dotyczące ochrony poszczepiennej oraz wpływu na zdrowie publiczne są istotnym elementem oceny skuteczności szczepienia MMR.12

Skuteczność ochrony przed chorobami docelowymi

Szczepionka MMR charakteryzuje się wysoką skutecznością w zapobieganiu trzem poważnym infekcjom wirusowym: odrze, śwince i różyczce. Ochrona immunologiczna rozwija się w ciągu dwóch tygodni od zaszczepienia, przy czym pełny schemat obejmujący dwie dawki zapewnia długotrwałą ochronę.12

Skuteczność szczepionki MMR przedstawia się następująco:

Badania wskazują, że większość osób zaszczepionych dwiema dawkami szczepionki MMR pozostaje chroniona przed odrą i różyczką przez całe życie. W przypadku świnki, odporność u niektórych osób może z czasem słabnąć, co może wymagać podania dodatkowej dawki w sytuacji wybuchu ogniska tej choroby.6

Złagodzenie przebiegu chorób u osób zaszczepionych

Istotnym aspektem prognostycznym jest fakt, że nawet w rzadkich przypadkach zachorowania na którąś z chorób mimo zaszczepienia, przebieg choroby jest zazwyczaj znacznie łagodniejszy. Dotyczy to szczególnie świnki, gdzie u osób zaszczepionych objawy są wyraźnie mniej nasilone.7 Chociaż zakażenie odrą po pełnym szczepieniu jest możliwe, jest to zjawisko bardzo rzadkie.1

Wpływ na zmniejszenie hospitalizacji

Badania retrospektywne wykazały znaczące zmniejszenie częstości hospitalizacji z powodu chorób zakaźnych u dzieci zaszczepionych MMR. Szczepionka wykazuje wysoką skuteczność ochronną przeciwko hospitalizacjom związanym z odrą i świnką (HR = 0,10; 95% CI: 0,03-0,34).1

Co istotne, ochronny wpływ szczepionki MMR wykracza poza choroby docelowe i obejmuje:

Wpływ momentu szczepienia na prognozę

Badania wskazują, że optymalny wiek podania pierwszej dawki szczepionki MMR (MCV1) może mieć istotny wpływ na skuteczność profilaktyki. Analiza optymalizacyjna sugeruje, że wiek ten powinien być dostosowany do lokalnej epidemiologii odry i może wahać się w przedziale 6-20 miesięcy.1

Czynniki wpływające na optymalny wiek szczepienia obejmują:

  • Intensywność transmisji wirusa odry w populacji – wyższa transmisja sugeruje niższy optymalny wiek szczepienia1
  • Poziom wyszczepialności populacji – niższe pokrycie szczepieniami wskazuje na korzyść z wcześniejszego szczepienia23
  • Średni wiek zakażenia w populacji po wprowadzeniu szczepionki2

Dostosowanie wieku podania pierwszej dawki szczepionki może pomóc w minimalizacji luk odpornościowych i zmniejszeniu zapadalności na odrę, przyczyniając się do osiągnięcia celów eliminacji choroby.4

Odporność zbiorowiskowa i wpływ populacyjny

Szczepionka MMR nie tylko zapewnia bezpośrednią ochronę osobom zaszczepionym, ale również przyczynia się do wytworzenia odporności zbiorowiskowej (odporności stadnej). Ten mechanizm prowadzi do pośredniej ochrony osób nieuodpornionych poprzez ograniczenie krążenia patogenów w populacji.1

W Stanach Zjednoczonych skoordynowane i skuteczne wysiłki w zakresie szczepień MMR doprowadziły do ogłoszenia eliminacji odry w 2000 roku, co pokazuje potencjał tej szczepionki w perspektywie długoterminowej.1 Jednak utrzymujące się ogniska odry w wielu krajach wskazują na istnienie luk w odporności wynikających z niepełnego lub nieskutecznego szczepienia.1

Bezpieczeństwo długoterminowe

Liczne badania naukowe potwierdziły brak związku między szczepionką MMR a poważnymi długoterminowymi skutkami zdrowotnymi, takimi jak zaburzenia ze spektrum autyzmu czy uszkodzenia mózgu. Warto przypomnieć, że kontrowersyjne badanie z 1998 roku sugerujące taki związek zostało wycofane w 2010 roku z powodu nieetycznych praktyk i nieprawidłowych informacji.12

Przeglądy systematyczne i metaanalizy konsekwentnie wykazują, że szczepionka MMR nie zwiększa ryzyka rozwoju następujących stanów:13

  • Zaburzenia ze spektrum autyzmu
  • Uszkodzenia mózgu
  • Choroby przewlekłe, takie jak astma czy cukrzyca
  • Opóźnienia rozwojowe
  • Choroba zapalna jelit

Kompleksowe dane wskazują, że częstość występowania tych schorzeń jest podobna u dzieci zaszczepionych i niezaszczepionych.2 Wieloletnie obserwacje potwierdzają korzystny profil bezpieczeństwa szczepionki MMR, co stanowi istotny element pozytywnej prognozy po szczepieniu.4

Podsumowanie prognozy po szczepieniu MMR

Szczepionka MMR zapewnia wysoki poziom ochrony przed odrą, świnką i różyczką, z efektywnością sięgającą 97-99% po pełnym schemacie szczepienia. Prognoza dla osób zaszczepionych obejmuje nie tylko ochronę przed chorobami docelowymi, ale również zmniejszenie ryzyka hospitalizacji z powodu innych infekcji, szczególnie chorób układu oddechowego.122

Nawet w rzadkich przypadkach zakażenia pomimo szczepienia, choroba przebiega łagodniej, co stanowi dodatkową korzyść. Długoterminowe bezpieczeństwo szczepionki zostało potwierdzone w licznych badaniach, które nie wykazały związku z zaburzeniami rozwojowymi czy chorobami przewlekłymi.11

Optymalny moment podania szczepionki może wpływać na jej skuteczność, co sugeruje potrzebę dostosowania harmonogramów szczepień do lokalnej sytuacji epidemiologicznej. Szczepienia MMR pozostają najważniejszym narzędziem w zapobieganiu odrze, śwince i różyczce, przyczyniając się do zmniejszenia zachorowalności i śmiertelności związanej z tymi chorobami.131

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 11.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1 MMR Vaccine (Measles, Mumps & Rubella Vaccination)
    https://my.clevelandclinic.org/health/procedures/mmr-vaccine
    The MMR vaccine is highly effective at protecting you and your child against three serious viral infections: measles, mumps and rubella. […] The MMR vaccine can provide strong protection against measles, mumps and rubella and the complications caused by these diseases. […] One dose of the MMR vaccine is: 93% effective in preventing measles. […] Two doses of the MMR vaccine are: 97% effective in preventing measles. […] Most people who receive the MMR vaccine are protected for life against measles and rubella. […] While the vaccine is also effective at protecting against mumps, some people may lose immunity to the disease over time and may need an additional dose during a mumps outbreak.
  • #1 MMR (measles, mumps and rubella) vaccine – NHS
    https://www.nhs.uk/vaccinations/mmr-vaccine/
    The MMR vaccine gives long-term protection against measles, mumps and rubella. […] 2 doses of the MMR vaccine gives you long-term protection. […] Protection starts within 2 weeks of having the MMR vaccine. […] After 2 doses: around 99% of people will be protected against measles and rubella; around 88% of people will be protected against mumps. […] If you get mumps after being vaccinated, the symptoms will usually be much milder.
  • #1 How dangerous is a measles outbreak? – UChicago Medicine
    https://www.uchicagomedicine.org/forefront/pediatrics-articles/2025/march/measles-is-still-a-very-dangerous-disease
    Thanks to a coordinated and highly effective effort to deliver the measles, mumps and rubella (MMR) vaccine, it was declared eliminated from the U.S. in 2000. […] More than 97% of people who receive two doses of the MMR vaccine develop immunity to measles. […] While it is possible to contract measles after two doses of the vaccine, it is very uncommon. […] Fortunately, for most people, measles is not life-threatening but the problem is that you can’t predict who will become seriously ill. […] However, if everyone is vaccinated, no one will die. […] The only way to prevent measles is with the MMR vaccine.
  • #1 The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5557224/
    Objectives: To evaluate the effectiveness of the measles-mumps-rubella (MMR) vaccine in reducing hospitalizations for infectious disease, targeted and not targeted, as well as from respiratory diseases in children in Rome. […] The vaccine was highly protective against measles and mumps hospitalizations (HR = 0.10; 95% CI: 0.03.0.34). […] MMR vaccination is effective for the primary prevention of target and not targeted infectious diseases and may also limit hospitalizations for respiratory diseases. […] In our study it resulted that receiving the live MMR vaccine is associated with a lower rate of hospital admissions for any target infectious disease, and for respiratory diseases in children. […] The association was particularly strong for lower respiratory tract infections (HR of 0.18; 95% CI: 0:07 to 00:48) and resulted highly protective against hospitalizations for all infectious diseases (HR: 0.29; 95% CI: 0:25 to 00:34).
  • #1 Estimating the optimal age for infant measles vaccination | Nature Communications
    https://www.nature.com/articles/s41467-024-53415-x
    The persistence of measles in many countries demonstrates large immunity gaps, resulting from incomplete or ineffective immunization with measles-containing vaccines (MCVs). MCV impact is determined, in part, by vaccination age. Infants who receive dose 1 (MCV1) at older ages have a reduced risk of vaccine failure, but also an increased risk of contracting infection before vaccination. […] We predict a large heterogeneity in the optimal MCV1 ages (range: 6-20 months), contrasting the homogeneity of observed recommendations worldwide. Furthermore, we show that the optimal age depends on the local epidemiology of measles, with a lower optimal age predicted in populations having lower vaccination coverage or suffering higher transmission. Overall, our results suggest the scope for public health authorities to tailor the recommended schedule for better measles control.
  • #1 Estimating the optimal age for infant measles vaccination | Nature Communications
    https://www.nature.com/articles/s41467-024-53415-x
    The optimal MCV1 age depends on the local epidemiology of measles. Specifically, we predict that populations with high measles transmission require a lower vaccination age. More generally, the impact of some influential factors of local epidemiology on the optimal age can be understood by considering their effect on the mean age of infection (MAI) and transmission after vaccine introduction. […] Our results suggest that in addition to increasing vaccine coverage, adjusting the recommended vaccination age could help minimize immunity gaps and reduce measles incidence, taking steps toward eventual elimination.
  • #1 The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5557224/
    Vaccination remains one of the safest and effective interventions available in public health for the primary prevention of infectious diseases, resulting in a medical practice that induces both direct and indirect immunity in individuals vaccinated (herd immunity). […] In conclusion, even if the study is not novel in the international panorama, we believe it adds some new insight, in particular for what concerns the protective effect of MMR vaccination against hospitalizations for respiratory diseases in children.
  • #1 The Truth About the MMR Vaccine
    https://www.healthline.com/health/mmr-vaccine
    The MMR vaccine, introduced in the United States in 1971, helps prevent the measles, the mumps, and rubella (German measles). This vaccine was a huge development in the battle to prevent these dangerous diseases. […] However, the MMR vaccine is no stranger to controversy. In 1998, a study published in The Lancet linked the vaccine to serious health risks in children, including autism and inflammatory bowel disease. […] But in 2010, the journal retracted that study, citing unethical practices and incorrect information. Since then, many research studies have looked for a connection between the MMR vaccine and these conditions. No connection has been found. […] The MMR vaccine protects against three major diseases: measles, mumps, and rubella (German measles). All three of these diseases can cause serious health complications. In rare cases, they can even lead to death.
  • #1 How effective and safe are measles vaccines? – Our World in Data
    https://ourworldindata.org/measles-vaccine-effectiveness-safety
    One dose of the MMR vaccine (the combined vaccine against measles, mumps, and rubella) reduces the chance of getting measles by around 95%. This means the chances were twenty times lower in the vaccinated. […] After two doses of the vaccine, the chances were twenty-five times lower than in unvaccinated children. Two doses are usually recommended because some children who don’t respond to the first dose become protected after the second. […] The review found no link between the MMR vaccine and many conditions (shown in gray). This includes autism, brain damage, and long-term conditions like asthma, diabetes, and developmental delays. Comprehensive data shows that children who are vaccinated have similar rates of autism and other conditions as children who are not vaccinated.
  • #1 The Truth About the MMR Vaccine
    https://www.healthline.com/health/mmr-vaccine
    The Western Journal of Medicine reported in 2001 that the number of autism diagnoses has been rising since 1979. However, the study didn’t find an increase in autism cases after the introduction of the MMR vaccine. Instead, the researchers found that the growing number of autism cases was most likely due to changes in how doctors diagnose autism. […] Since that article was published, multiple studies have found no link between the MMR vaccine and autism. These include studies published in the journals Vaccine and PLoS ONE. […] In addition, a 2014 study published in Pediatrics reviewed over 67 studies on the safety of vaccines in the United States and concluded that the strength of evidence is high that MMR vaccine is not associated with the onset of autism in children. […] And a 2015 study published in the Journal of the American Medical Association found that even among children who have siblings with autism, there was no increased risk of autism linked with the MMR vaccine. […] Furthermore, the Institute of Medicine and the World Health Organization both agree: there is no evidence that the MMR vaccine causes autism.
  • #1 Expanding Measles Outbreak in the United States and Guidance for the Upcoming Travel Season | HAN | CDC
    https://www.cdc.gov/han/php/notices/han00522.html
    Measles-mumps-rubella (MMR) vaccination remains the most important tool for preventing measles. […] Most of the 222 cases are among children who had not received the MMR vaccine. […] Two doses of MMR vaccine provide better protection (97%) against measles than one dose (93%).
  • #2 Expanding Measles Outbreak in the United States and Guidance for the Upcoming Travel Season | HAN | CDC
    https://www.cdc.gov/han/php/notices/han00522.html
    Measles-mumps-rubella (MMR) vaccination remains the most important tool for preventing measles. […] Most of the 222 cases are among children who had not received the MMR vaccine. […] Two doses of MMR vaccine provide better protection (97%) against measles than one dose (93%).
  • #2 MMR Vaccine (Measles, Mumps & Rubella Vaccination)
    https://my.clevelandclinic.org/health/procedures/mmr-vaccine
    The MMR vaccine is highly effective at protecting you and your child against three serious viral infections: measles, mumps and rubella. […] The MMR vaccine can provide strong protection against measles, mumps and rubella and the complications caused by these diseases. […] One dose of the MMR vaccine is: 93% effective in preventing measles. […] Two doses of the MMR vaccine are: 97% effective in preventing measles. […] Most people who receive the MMR vaccine are protected for life against measles and rubella. […] While the vaccine is also effective at protecting against mumps, some people may lose immunity to the disease over time and may need an additional dose during a mumps outbreak.
  • #2 The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5557224/
    Objectives: To evaluate the effectiveness of the measles-mumps-rubella (MMR) vaccine in reducing hospitalizations for infectious disease, targeted and not targeted, as well as from respiratory diseases in children in Rome. […] The vaccine was highly protective against measles and mumps hospitalizations (HR = 0.10; 95% CI: 0.03.0.34). […] MMR vaccination is effective for the primary prevention of target and not targeted infectious diseases and may also limit hospitalizations for respiratory diseases. […] In our study it resulted that receiving the live MMR vaccine is associated with a lower rate of hospital admissions for any target infectious disease, and for respiratory diseases in children. […] The association was particularly strong for lower respiratory tract infections (HR of 0.18; 95% CI: 0:07 to 00:48) and resulted highly protective against hospitalizations for all infectious diseases (HR: 0.29; 95% CI: 0:25 to 00:34).
  • #2 Estimating the optimal age for infant measles vaccination | Nature Communications
    https://www.nature.com/articles/s41467-024-53415-x
    The persistence of measles in many countries demonstrates large immunity gaps, resulting from incomplete or ineffective immunization with measles-containing vaccines (MCVs). MCV impact is determined, in part, by vaccination age. Infants who receive dose 1 (MCV1) at older ages have a reduced risk of vaccine failure, but also an increased risk of contracting infection before vaccination. […] We predict a large heterogeneity in the optimal MCV1 ages (range: 6-20 months), contrasting the homogeneity of observed recommendations worldwide. Furthermore, we show that the optimal age depends on the local epidemiology of measles, with a lower optimal age predicted in populations having lower vaccination coverage or suffering higher transmission. Overall, our results suggest the scope for public health authorities to tailor the recommended schedule for better measles control.
  • #2 Estimating the optimal age for infant measles vaccination | Nature Communications
    https://www.nature.com/articles/s41467-024-53415-x
    The optimal MCV1 age depends on the local epidemiology of measles. Specifically, we predict that populations with high measles transmission require a lower vaccination age. More generally, the impact of some influential factors of local epidemiology on the optimal age can be understood by considering their effect on the mean age of infection (MAI) and transmission after vaccine introduction. […] Our results suggest that in addition to increasing vaccine coverage, adjusting the recommended vaccination age could help minimize immunity gaps and reduce measles incidence, taking steps toward eventual elimination.
  • #2 The Truth About the MMR Vaccine
    https://www.healthline.com/health/mmr-vaccine
    The Western Journal of Medicine reported in 2001 that the number of autism diagnoses has been rising since 1979. However, the study didn’t find an increase in autism cases after the introduction of the MMR vaccine. Instead, the researchers found that the growing number of autism cases was most likely due to changes in how doctors diagnose autism. […] Since that article was published, multiple studies have found no link between the MMR vaccine and autism. These include studies published in the journals Vaccine and PLoS ONE. […] In addition, a 2014 study published in Pediatrics reviewed over 67 studies on the safety of vaccines in the United States and concluded that the strength of evidence is high that MMR vaccine is not associated with the onset of autism in children. […] And a 2015 study published in the Journal of the American Medical Association found that even among children who have siblings with autism, there was no increased risk of autism linked with the MMR vaccine. […] Furthermore, the Institute of Medicine and the World Health Organization both agree: there is no evidence that the MMR vaccine causes autism.
  • #2 How effective and safe are measles vaccines? – Our World in Data
    https://ourworldindata.org/measles-vaccine-effectiveness-safety
    One dose of the MMR vaccine (the combined vaccine against measles, mumps, and rubella) reduces the chance of getting measles by around 95%. This means the chances were twenty times lower in the vaccinated. […] After two doses of the vaccine, the chances were twenty-five times lower than in unvaccinated children. Two doses are usually recommended because some children who don’t respond to the first dose become protected after the second. […] The review found no link between the MMR vaccine and many conditions (shown in gray). This includes autism, brain damage, and long-term conditions like asthma, diabetes, and developmental delays. Comprehensive data shows that children who are vaccinated have similar rates of autism and other conditions as children who are not vaccinated.
  • #2 MMR (measles, mumps and rubella) vaccine – NHS
    https://www.nhs.uk/vaccinations/mmr-vaccine/
    The MMR vaccine gives long-term protection against measles, mumps and rubella. […] 2 doses of the MMR vaccine gives you long-term protection. […] Protection starts within 2 weeks of having the MMR vaccine. […] After 2 doses: around 99% of people will be protected against measles and rubella; around 88% of people will be protected against mumps. […] If you get mumps after being vaccinated, the symptoms will usually be much milder.
  • #2 How dangerous is a measles outbreak? – UChicago Medicine
    https://www.uchicagomedicine.org/forefront/pediatrics-articles/2025/march/measles-is-still-a-very-dangerous-disease
    Thanks to a coordinated and highly effective effort to deliver the measles, mumps and rubella (MMR) vaccine, it was declared eliminated from the U.S. in 2000. […] More than 97% of people who receive two doses of the MMR vaccine develop immunity to measles. […] While it is possible to contract measles after two doses of the vaccine, it is very uncommon. […] Fortunately, for most people, measles is not life-threatening but the problem is that you can’t predict who will become seriously ill. […] However, if everyone is vaccinated, no one will die. […] The only way to prevent measles is with the MMR vaccine.
  • #3 MMR Vaccine (Measles, Mumps & Rubella Vaccination)
    https://my.clevelandclinic.org/health/procedures/mmr-vaccine
    The MMR vaccine is highly effective at protecting you and your child against three serious viral infections: measles, mumps and rubella. […] The MMR vaccine can provide strong protection against measles, mumps and rubella and the complications caused by these diseases. […] One dose of the MMR vaccine is: 93% effective in preventing measles. […] Two doses of the MMR vaccine are: 97% effective in preventing measles. […] Most people who receive the MMR vaccine are protected for life against measles and rubella. […] While the vaccine is also effective at protecting against mumps, some people may lose immunity to the disease over time and may need an additional dose during a mumps outbreak.
  • #3 The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5557224/
    Objectives: To evaluate the effectiveness of the measles-mumps-rubella (MMR) vaccine in reducing hospitalizations for infectious disease, targeted and not targeted, as well as from respiratory diseases in children in Rome. […] The vaccine was highly protective against measles and mumps hospitalizations (HR = 0.10; 95% CI: 0.03.0.34). […] MMR vaccination is effective for the primary prevention of target and not targeted infectious diseases and may also limit hospitalizations for respiratory diseases. […] In our study it resulted that receiving the live MMR vaccine is associated with a lower rate of hospital admissions for any target infectious disease, and for respiratory diseases in children. […] The association was particularly strong for lower respiratory tract infections (HR of 0.18; 95% CI: 0:07 to 00:48) and resulted highly protective against hospitalizations for all infectious diseases (HR: 0.29; 95% CI: 0:25 to 00:34).
  • #3 Estimating the optimal age for infant measles vaccination | Nature Communications
    https://www.nature.com/articles/s41467-024-53415-x
    The optimal MCV1 age depends on the local epidemiology of measles. Specifically, we predict that populations with high measles transmission require a lower vaccination age. More generally, the impact of some influential factors of local epidemiology on the optimal age can be understood by considering their effect on the mean age of infection (MAI) and transmission after vaccine introduction. […] Our results suggest that in addition to increasing vaccine coverage, adjusting the recommended vaccination age could help minimize immunity gaps and reduce measles incidence, taking steps toward eventual elimination.
  • #3 The Truth About the MMR Vaccine
    https://www.healthline.com/health/mmr-vaccine
    The Western Journal of Medicine reported in 2001 that the number of autism diagnoses has been rising since 1979. However, the study didn’t find an increase in autism cases after the introduction of the MMR vaccine. Instead, the researchers found that the growing number of autism cases was most likely due to changes in how doctors diagnose autism. […] Since that article was published, multiple studies have found no link between the MMR vaccine and autism. These include studies published in the journals Vaccine and PLoS ONE. […] In addition, a 2014 study published in Pediatrics reviewed over 67 studies on the safety of vaccines in the United States and concluded that the strength of evidence is high that MMR vaccine is not associated with the onset of autism in children. […] And a 2015 study published in the Journal of the American Medical Association found that even among children who have siblings with autism, there was no increased risk of autism linked with the MMR vaccine. […] Furthermore, the Institute of Medicine and the World Health Organization both agree: there is no evidence that the MMR vaccine causes autism.
  • #3 How dangerous is a measles outbreak? – UChicago Medicine
    https://www.uchicagomedicine.org/forefront/pediatrics-articles/2025/march/measles-is-still-a-very-dangerous-disease
    Thanks to a coordinated and highly effective effort to deliver the measles, mumps and rubella (MMR) vaccine, it was declared eliminated from the U.S. in 2000. […] More than 97% of people who receive two doses of the MMR vaccine develop immunity to measles. […] While it is possible to contract measles after two doses of the vaccine, it is very uncommon. […] Fortunately, for most people, measles is not life-threatening but the problem is that you can’t predict who will become seriously ill. […] However, if everyone is vaccinated, no one will die. […] The only way to prevent measles is with the MMR vaccine.
  • #4 MMR (measles, mumps and rubella) vaccine – NHS
    https://www.nhs.uk/vaccinations/mmr-vaccine/
    The MMR vaccine gives long-term protection against measles, mumps and rubella. […] 2 doses of the MMR vaccine gives you long-term protection. […] Protection starts within 2 weeks of having the MMR vaccine. […] After 2 doses: around 99% of people will be protected against measles and rubella; around 88% of people will be protected against mumps. […] If you get mumps after being vaccinated, the symptoms will usually be much milder.
  • #4 The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5557224/
    Objectives: To evaluate the effectiveness of the measles-mumps-rubella (MMR) vaccine in reducing hospitalizations for infectious disease, targeted and not targeted, as well as from respiratory diseases in children in Rome. […] The vaccine was highly protective against measles and mumps hospitalizations (HR = 0.10; 95% CI: 0.03.0.34). […] MMR vaccination is effective for the primary prevention of target and not targeted infectious diseases and may also limit hospitalizations for respiratory diseases. […] In our study it resulted that receiving the live MMR vaccine is associated with a lower rate of hospital admissions for any target infectious disease, and for respiratory diseases in children. […] The association was particularly strong for lower respiratory tract infections (HR of 0.18; 95% CI: 0:07 to 00:48) and resulted highly protective against hospitalizations for all infectious diseases (HR: 0.29; 95% CI: 0:25 to 00:34).
  • #4 Estimating the optimal age for infant measles vaccination | Nature Communications
    https://www.nature.com/articles/s41467-024-53415-x
    The optimal MCV1 age depends on the local epidemiology of measles. Specifically, we predict that populations with high measles transmission require a lower vaccination age. More generally, the impact of some influential factors of local epidemiology on the optimal age can be understood by considering their effect on the mean age of infection (MAI) and transmission after vaccine introduction. […] Our results suggest that in addition to increasing vaccine coverage, adjusting the recommended vaccination age could help minimize immunity gaps and reduce measles incidence, taking steps toward eventual elimination.
  • #4 The Truth About the MMR Vaccine
    https://www.healthline.com/health/mmr-vaccine
    The Western Journal of Medicine reported in 2001 that the number of autism diagnoses has been rising since 1979. However, the study didn’t find an increase in autism cases after the introduction of the MMR vaccine. Instead, the researchers found that the growing number of autism cases was most likely due to changes in how doctors diagnose autism. […] Since that article was published, multiple studies have found no link between the MMR vaccine and autism. These include studies published in the journals Vaccine and PLoS ONE. […] In addition, a 2014 study published in Pediatrics reviewed over 67 studies on the safety of vaccines in the United States and concluded that the strength of evidence is high that MMR vaccine is not associated with the onset of autism in children. […] And a 2015 study published in the Journal of the American Medical Association found that even among children who have siblings with autism, there was no increased risk of autism linked with the MMR vaccine. […] Furthermore, the Institute of Medicine and the World Health Organization both agree: there is no evidence that the MMR vaccine causes autism.
  • #5 MMR (measles, mumps and rubella) vaccine – NHS
    https://www.nhs.uk/vaccinations/mmr-vaccine/
    The MMR vaccine gives long-term protection against measles, mumps and rubella. […] 2 doses of the MMR vaccine gives you long-term protection. […] Protection starts within 2 weeks of having the MMR vaccine. […] After 2 doses: around 99% of people will be protected against measles and rubella; around 88% of people will be protected against mumps. […] If you get mumps after being vaccinated, the symptoms will usually be much milder.
  • #5 The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5557224/
    Vaccination remains one of the safest and effective interventions available in public health for the primary prevention of infectious diseases, resulting in a medical practice that induces both direct and indirect immunity in individuals vaccinated (herd immunity). […] In conclusion, even if the study is not novel in the international panorama, we believe it adds some new insight, in particular for what concerns the protective effect of MMR vaccination against hospitalizations for respiratory diseases in children.
  • #6 MMR Vaccine (Measles, Mumps & Rubella Vaccination)
    https://my.clevelandclinic.org/health/procedures/mmr-vaccine
    The MMR vaccine is highly effective at protecting you and your child against three serious viral infections: measles, mumps and rubella. […] The MMR vaccine can provide strong protection against measles, mumps and rubella and the complications caused by these diseases. […] One dose of the MMR vaccine is: 93% effective in preventing measles. […] Two doses of the MMR vaccine are: 97% effective in preventing measles. […] Most people who receive the MMR vaccine are protected for life against measles and rubella. […] While the vaccine is also effective at protecting against mumps, some people may lose immunity to the disease over time and may need an additional dose during a mumps outbreak.
  • #7 MMR (measles, mumps and rubella) vaccine – NHS
    https://www.nhs.uk/vaccinations/mmr-vaccine/
    The MMR vaccine gives long-term protection against measles, mumps and rubella. […] 2 doses of the MMR vaccine gives you long-term protection. […] Protection starts within 2 weeks of having the MMR vaccine. […] After 2 doses: around 99% of people will be protected against measles and rubella; around 88% of people will be protected against mumps. […] If you get mumps after being vaccinated, the symptoms will usually be much milder.

Zobacz więcej

odporność zbiorowiskowa świnka zaburzenia spektrum autyzmu odporność immunologiczna śmiertelność odporność stadna ognisko choroby choroba zapalna jelit wyszczepialność patogen schemat szczepienia przebieg choroby hospitalizacja eliminacja choroby epidemiologia różyczka transmisja wirusa choroby układu oddechowego odra infekcja dróg oddechowych szczepionka MMR infekcja wirusowa choroba zakaźna zapadalność